Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cord blood-derived mesenchymal stem cells (M.D. Anderson)
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Cord blood-derived mesenchymal stem cells (MSCs) are an investigational cell therapy developed by the M.D. Anderson Cancer Center for the treatment of moderate to critical COVID-19 pneumonia and associated acute respiratory distress syndrome (ARDS). These cells are multipotent stromal cells isolated from healthy, unrelated donor umbilical cord blood and expanded in vitro. The therapeutic rationale for using MSCs in ARDS is based on their potent immunomodulatory and anti-inflammatory properties. Upon intravenous administration, these cells are thought to sequester in the pulmonary microvasculature where they secrete paracrine factors that mitigate the hyperinflammatory 'cytokine storm,' reduce alveolar-capillary membrane permeability, and promote the repair of damaged lung tissue.
- Other names
- umbilical cord blood-derived mesenchymal stem cellsUC-MSCsMesenchymal Stem Cell
Beyond the preview
Go deeper on cord blood-derived mesenchymal stem cells (M.D. Anderson).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cord blood-derived mesenchymal stem cells (M.D. Anderson).